Colin Powell has died of complications from COVID-19 after receiving treatment for a blood cancer.
Photo by stocklight/Shutterstock.com.
Colin L. Powell, the first Black United States Secretary of State, has died of complications of COVID-19, according to a statement from his family.
Powell, 84, had also recently been receiving treatment for multiple myeloma, according to his longtime aide, Peggy Cifrino.
The statement from his family noted he was “fully vaccinated” but did not go into detail about the complications that led to his death. It is also not known if Powell had received a booster shot.
Recently released study results from the Leukemia & Lymphoma Society showed that more than half of patients with B-cell blood cancers who did not have detectable antibodies after the first two doses of a COVID-19 vaccine produced antibodies after a third dose. The results, however, indicated that some patients may not have a full antibody response after the booster dose.
In a statement, former President George W. Bush commemorated Powell’s life and praised his countless years of service.
“He was a great public servant, starting with his time as a soldier during Vietnam,” Bush said. “Many presidents relied on General Powell’s counsel and experience. …He was such a favorite of presidents that he earned the Presidential Medal of Freedom – twice. He was highly respected at home and abroad. And most important, Colin was a family man and friend.”
Powell had previously received treatment for prostate cancer in 2003 at the age of 66.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy-Related Cancer
November 29th 2023The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.
Read More
Cancer Vaccine Plus Keytruda Improves Survival Without Relapse in Resected Melanoma
November 7th 2023Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.
Read More
Survival May Not Differ by Race in Multiple Myeloma Treated With Abecma
November 6th 2023Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival.
Read More